COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Autologous/Allogeneic Progenitor Stem Cell Therapy for Congestive Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00128258
Recruitment Status : Terminated (study no longer at pittsburgh)
First Posted : August 9, 2005
Last Update Posted : January 19, 2018
Information provided by (Responsible Party):
Amit N. Patel MD MS, Amit, Patel N, M.D.

Brief Summary:

This research study is being performed to find out more information about the safety and effectiveness of injecting bone marrow progenitor cells (BMPCs) from one's own hip bone into one's heart muscle. The BMPCs are the cells from which the different types of blood and other cells grow.

In patients with heart failure, the heart muscle does not pump well. Over a period of years, this continues to get worse until the patient dies of heart failure. The investigators are trying to find out if the injection of these BMPCs can make a change in the functioning of these areas of the heart muscle. Data from studies around the world have suggested that when patients with heart failure receive these cells by direct injection into their hearts they show signs of recovered heart function, however, there has been no evidence from actual studies of the cells of the patient's hearts to show how this process works. It is the investigator's plan to inject an eligible participant's heart with cells that are from one's own bone marrow during an operation to receive a ventricular assist device (VAD) or partial artificial heart and then to study the function of the heart while awaiting a heart transplant. The investigators will then examine the heart after it has been removed as part of the regular heart transplant operation for any microscopic changes (changes too small to be seen by the unaided eye but large enough to be studied under a microscope) at the site where the cells are injected. Participants will have no change in the chances of receiving a heart transplant by agreeing to participate in this study. There will also be no delay in receiving a VAD operation while waiting to participate in this study. This Phase I study has been cleared by the Food and Drug Administration (FDA) to enroll and treat patients. The Center for Biologics Evaluation and Research Investigational New Drug number (IND BB #) is 12304. (A Phase I trial is a research study using techniques or products in the first-stage or for the first time in human subjects).

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Procedure: Injection of bone marrow cells in the heart Biological: Biological bone marrow cell therapy Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study: Autologous/Allogeneic Bone Marrow Progenitor Cell Treatment for Heart Failure
Actual Study Start Date : May 1, 2005
Actual Primary Completion Date : December 1, 2016
Actual Study Completion Date : December 1, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: open
open treatment
Procedure: Injection of bone marrow cells in the heart
Biological implant into the heart

Biological: Biological bone marrow cell therapy
Biological implant into the heart

Primary Outcome Measures :
  1. Heart function at 3 months after implant [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Toxicity [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >=18 years.
  • Congestive heart failure with ejection fraction <= 35.
  • Candidates for ventricular device placement as a bridge to transplant.
  • Serum bilirubin, SGOT and SGPT <= 2.5 times the upper level of normal.
  • Serum creatinine < 2.0 times normal or no dialysis.
  • New York Heart Association (NYHA) performance status > 3.
  • Negative pregnancy test (in women with childbearing potential).

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • History of prior radiation exposure.
  • History of bone marrow disorder.
  • History of abnormal bleeding or clotting.
  • History of liver cirrhosis.
  • Inability to obtain 1 x 10^6 CD 34+ cells after bone marrow processing.
  • Acute myocardial infarction < 6 days from acute event.
  • Prior malignancy in the 5 years before treatment in this study (other than curatively treated carcinoma in-situ of the cervix or non-melanoma skin cancer).
  • Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
  • Eligible for destination ventricular assist device placement.
  • Unable to have 250cc bone marrow harvested.

Layout table for additonal information
Responsible Party: Amit N. Patel MD MS, Director, Amit, Patel N, M.D. Identifier: NCT00128258    
Other Study ID Numbers: #:0504126
First Posted: August 9, 2005    Key Record Dates
Last Update Posted: January 19, 2018
Last Verified: January 2018
Keywords provided by Amit N. Patel MD MS, Amit, Patel N, M.D.:
Stem Cell
Heart Failure
Bone Marrow
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases